Investigation of complement activation product c4d as a diagnostic and prognostic biomarker for lung cancer.

ABSTRACT:

Background

There is a medical need for diagnostic biomarkers in lung cancer. We evaluated the diagnostic performance of complement activation fragments.

Methods

We assessed complement activation in four bronchial epithelial and seven lung cancer cell lines. C4d, a degradation product of complement activation, was determined in 90 primary lung tumors; bronchoalveolar lavage supernatants from patients with lung cancer (n = 50) and nonmalignant respiratory diseases (n = 22); and plasma samples from advanced (n = 50) and early lung cancer patients (n = 84) subjects with inflammatory lung diseases (n = 133), and asymptomatic individuals enrolled in a lung cancer computed tomography screening program (n = 190). Two-sided P values were calculated by Mann-Whitney U test.

Results<

SUBMITTER: Ajona D 

PROVIDER: S-EPMC3776260 | biostudies-literature | 2013 Sep

REPOSITORIES: biostudies-literature